SYK - Stryker Corporation
| Previous Close | 168.69 |
| Open | 168.60 |
| Bid | 167.17 x 800 |
| Ask | 175.00 x 2200 |
| Day's Range | 167.63 - 170.21 |
| 52 Week Range | 137.70 - 179.84 |
| Volume | 1,315,536 |
| Avg. Volume | 1,384,768 |
| Market Cap | 63.571B |
| Beta | 0.40 |
| PE Ratio (TTM) | 60.02 |
| EPS (TTM) | 2.83 |
| Earnings Date | Oct 24, 2018 - Oct 29, 2018 |
| Forward Dividend & Yield | 1.88 (1.13%) |
| Ex-Dividend Date | 2018-09-27 |
| 1y Target Est | 183.93 |
Market Realist•10 days agoWhat Does Tandem Diabetes Care’s Valuation Trend Indicate?
From $8.80 on May 8, Tandem Diabetes Care’s (TNDM) stock price steadily rose to a high of $33.44 on August 3. It recovered after that to its current level of $30.75.
Market Realist•10 days agoGauging Dentsply Sirona’s Valuation Trend and Recent Acquisitions
Dentsply Sirona (XRAY) has lowered its guidance for fiscal 2018. It now expects adjusted EPS of $2–$2.15 compared to the previous estimate of $2.55–$2.65. The decrease represents Dentsply’s expectation of a decline in revenue for the remainder of 2018, driven by higher levels of inventory destocking at its dealer partners.
- Market Realist•10 days ago
Dentsply Sirona’s Segments: Q2 2018 Performance
Since its second-quarter earnings release on July 7, Dentsply Sirona (XRAY) stock has plummeted ~20%. In this series, we’ll explore its financial performance, how its segments are performing, its recent acquisitions, its valuation metrics, and what analysts expect in the coming months. Dentsply Sirona is a leading global manufacturer of professional dental products and technologies.
- GlobeNewswire•10 days ago
Market Trends Toward New Normal in ING Group, N.V, Altaba, Steel Dynamics, The TJX Companies, Colgate-Palmolive, and Stryker — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, Aug. 09, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ING ...
- Zacks•12 days ago
DENTSPLY (XRAY) Beats on Q2 Earnings, Lowers 2018 Guidance
DENTSPLY (XRAY) gains from solid year-over-year international revenue growth in Q2; high impairment charges in the quarter mars results.
Market Realist•13 days agoHologic Expects Robust Earnings Growth for Fiscal 2018
In its fiscal third-quarter conference call, Hologic (HOLX) narrowed the projected range of its fiscal 2018 EPS from $2.22–$2.27 to $2.24–$2.26. Considering the midpoint of the updated EPS guidance range, the company expects YoY (year-over-year) EPS growth of ~10.8% for fiscal 2018.
Market Realist•15 days agoHologic Raised Its Revenue Guidance for Fiscal 2018
During its fiscal third quarter conference call, Hologic (HOLX) raised its fiscal 2018 non-GAAP revenue guidance from $3.18 billion–$3.21 billion to ~$3.21 billion–$3.22 billion. So, its YoY (year-over-year) reported revenue growth rate for fiscal 2018 is expected to be 4.8%–5.3%, higher than the previously projected range of 4.0%–4.9%.
- Market Realist•15 days ago
Analysts’ Recommendations for Hologic and Its Peers in August
In the fiscal third quarter, Hologic reported non-GAAP EPS of ~$0.58, which was a YoY rise of 16.0%. Hologic surpassed its revenue and EPS guidance for the fiscal third quarter. Hologic’s Diagnostics business posted a recovery compared to the fiscal second quarter, and its Surgical business has posted gradual improvement since the fiscal first quarter.
- Zacks•15 days ago
Medical Product Stock Earnings on Aug 6: CAH, HSIC & More
The Medical product market gains momentum owing to the recent two-year suspension of the controversial 2.3% Medical Device tax.
- Zacks•16 days ago
Pacific Biosciences (PACB) Loss In Line With Estimates in Q2
Strong performance in Product revenues boosts Pacific Biosciences (PACB) in Q2. Sequel order improves year over year.
- Zacks•16 days ago
DexCom (DXCM) Beats Q2 Earnings Estimates, Raises '18 View
Solid contribution from the Sensor, Transmitter and Receiver segments drives DexCom's (DXCM) Q2 results.
- Zacks•16 days ago
Integer Holdings (ITGR) Beats on Q2 Earnings, '18 View Solid
Integer Holdings (ITGR) gains on solid Cardio & Vascular revenues and high organic sales; a solid guidance raises optimism.
- Zacks•16 days ago
DaVita (DVA) Beats Earnings and Revenue Estimates in Q2
Year-over-year growth in net dialysis and related lab patient service revenues boost DaVita's (DVA) bottom line in Q2.
- Zacks•17 days ago
Express Scripts (ESRX) Q2 Earnings Beat, Network Claims Fall
Express Scripts (ESRX) witnesses year-over-year decline in adjusted network claims in Q2, thanks to the loss of certain public sector clients.
- Zacks•17 days ago
AmerisourceBergen (ABC) Beats on Q3 Earnings & Revenues
AmerisourceBergen (ABC) registers strong growth in the Pharmaceutical Distribution segment and the World Courier business in Q3.
- Zacks•18 days ago
Fresenius Medical (FMS) Misses Q2 Earnings & Sales Estimates
Lower peritoneal dialysis sales in Q2 hurt Fresenius Medical (FMS); solid geographical performance encourages.
- Zacks•18 days ago
Medical Product Earnings Lineup for Aug 2: ABC, BDX & More
Strong R&D focus is likely to be the key driver of the Medical Product space in Q2.
- Zacks•18 days ago
Ecolab (ECL) Q2 Earnings In Line, Revenues Beat Estimates
Solid performance in the Global Industrial and Global Institutional segments boost Ecolab's (ECL) top line in Q2.
- Zacks•19 days ago
athenahealth (ATHN) Beats on Q2 Earnings, Raises '19 View
An upbeat 2018 guidance instills investor's optimism for athenahealth (ATHN). However, lackluster performance in the Implementation and other segment is a persistent headwind.
- Barrons.com•22 days ago
[$$] Visa Still Offers Upside, Says Raymond James
Microsoft • MSFT-Nasdaq Outperform • Price $104.40 on July 19 by Evercore ISI Expectations were running high into Microsoft’s fiscal fourth-quarter results, and it delivered another phenomenal quarter highlighted by strong commercial bookings (up 18% in constant-currency gains) and Azure (cloud apps) growth up 85% [all figures in constant currency]. While the commercial cloud business (up 50%, to $6.9 billion, in revenue) continues to garner much of the attention, we believe Microsoft saw strong performance across all of its business lines, with continued acceleration in LinkedIn (up 34%) and gaming (up 38%). Looking forward, the company continues to see a strong backdrop for its commercial offerings, and we expect another year of double-digit top-line growth and some modest operating leverage (despite a big jump in capital expenditures in fiscal 2018).
Market Realist•23 days agoVarian Medical Systems’ Fiscal Q3 2018 Performance
Varian Medical Systems (VAR) reported its fiscal Q3 2018 results on July 25. Net sales surged 12% YoY (year-over-year) from $632.8 million to $709.1 million.
Market Realist•24 days agoStryker Reports Revenue Growth of 10.3% in Second Quarter
Stryker (SYK) released its second-quarter results on July 24. The company’s net sales surged 10.3% from $3.01 billion in Q2 2017 to $3.3 billion in Q2 2018. Stryker’s Neurotechnology and Spine segment, which grew by 19.4%, contributed the most to Stryker’s revenue growth. Sales from its other two segments, Orthopaedics and MedSurg, grew by 7.6% and 8.9%, respectively. The increase in the company’s revenues came from higher unit volumes, partially offset by lower prices.
- Investing.com•24 days ago
Stocks - GM, Boeing Slump in Pre-market; Coca-Cola Gains; AT&T Drops
Investing.com - Stocks in focus in pre-market trade Wednesday:
- Zacks•24 days ago
Stryker (SYK) Beats on Q2 Earnings, International Sales Up
Stryker (SYK) gains from solid segmental performance in Q2.
- ACCESSWIRE•25 days ago
Today's Research Reports on Trending Tickers: Nevro and Stryker
NEW YORK, NY / ACCESSWIRE / July 25, 2018 / U.S. markets finished moderately higher on Tuesday, fueled by strong corporate earnings as Google quarterly results topped expectations. The Dow Jones Industrial ...
